Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | CHIR-124 + SN-38 |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
CHIR-124 | CHIR124 | CHK1 Inhibitor 18 | CHIR-124 is a selective inhibitor of CHK1, which may enhance sensitivity of tumor cells to chemotherapeutic agents (PMID: 17255282, PMID: 22244109). | |
SN-38 | SN 38|SN38 | TOPO Inhibitor (Pan) 3 | SN-38 is a metabolite of the topoisomerase inhibitor irinotecan, which causes cell cycle arrest and apoptotic induction, potentially leading to tumor growth inhibition (PMID: 21609311). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
TP53 loss | colon cancer | sensitive | CHIR-124 + SN-38 | Preclinical - Cell culture | Actionable | In a preclinical study, a colon cancer cell line deficient in TP53 demonstrated increased sensitivity to sequential treatment with SN-38 and CHIR-124 compared to cells with wild-type TP53, resulting in increased apoptosis and micronucleation in culture (PMID: 17255282). | 17255282 |
TP53 inact mut | breast carcinoma | predicted - sensitive | CHIR-124 + SN-38 | Preclinical - Cell culture | Actionable | In a preclinical study, SN-38 and CHIR-124 demonstrated synergy in a breast carcinoma cell line with defective TP53, resulting in increased cell cycle arrest and apoptosis in culture (PMID: 17255282). | 17255282 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|